Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 15/05/2024 am IST 5-day change 1st Jan Change
38.27 USD -1.37% Intraday chart for Ionis Pharmaceuticals, Inc. -6.50% -24.35%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 599M 49.99B Sales 2025 * 767M 64B Capitalization 5.58B 466B
Net income 2024 * -575M -48B Net income 2025 * -518M -43.24B EV / Sales 2024 * 8.37 x
Net cash position 2024 * 567M 47.33B Net Debt 2025 * 318M 26.55B EV / Sales 2025 * 7.69 x
P/E ratio 2024 *
-10.1 x
P/E ratio 2025 *
-11.5 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.37%
1 week-6.50%
Current month-7.25%
1 month-8.31%
3 months-22.01%
6 months-22.14%
Current year-24.35%
More quotes
1 week
38.26
Extreme 38.26
40.18
1 month
38.26
Extreme 38.26
43.76
Current year
38.26
Extreme 38.26
54.44
1 year
34.99
Extreme 34.985
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 01/12/01
Founder 62 10/89/10
Director of Finance/CFO 62 01/00/01
Members of the board TitleAgeSince
Chairman 72 03/14/03
Founder 62 10/89/10
Director/Board Member 70 10/19/10
More insiders
Date Price Change Volume
14/24/14 38.27 -1.37% 983,112
13/24/13 38.8 -0.72% 1,045,266
10/24/10 39.08 -0.99% 895,065
09/24/09 39.47 -1.72% 1,300,598
08/24/08 40.16 -1.88% 1,527,136

Delayed Quote Nasdaq, May 15, 2024 at 01:30 am IST

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
38.27 USD
Average target price
57.95 USD
Spread / Average Target
+51.42%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW